In this article, we will list the 5 Small Cap Stocks with Potential to Rise 1000 Percent. Please visit 10 Small Cap Stocks with Potential to Rise 1000 Percent if you’d like to see an extended list.

For this article, we screened small-cap stocks with market capitalizations between $300 million and $2 billion. We then focused on companies with unusually high implied upside based on consensus analyst price targets, while avoiding stocks whose upside case relied solely on a single aggressive analyst estimate.

The final list was ranked by implied upside to consensus price target, from highest to lowest. Since exact 1,000% gains are speculative rather than measurable, the screen favored stocks with several hundred percent upside potential and broader analyst support.

5. Cabaletta Bio, Inc. (NASDAQ:CABA)

Cabaletta Bio, Inc. (NASDAQ:CABA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s 2026 story is focused on rese-cel, an experimental cell therapy being developed for autoimmune diseases, where the immune system mistakenly attacks the body. In its May 14 first-quarter update, Cabaletta said enrollment was progressing in a small registrational study of rese-cel in myositis, a group of rare autoimmune muscle diseases that can cause weakness and inflammation. If the study succeeds, Cabaletta expects it could support the company’s first planned application for FDA approval of rese-cel in myositis in 2027.

The update also gave investors a clearer timeline for upcoming clinical data. Cabaletta said it expects more results in the second half of 2026 from rese-cel studies in pemphigus vulgaris and lupus, along with data from patients receiving higher doses. The company also raised $150 million through a registered direct offering in May, with participation from investors including Bain Capital Life Sciences, Cormorant Asset Management, and Eli Lilly and Company. Cabaletta ended the first quarter with $116.6 million in cash, cash equivalents, and short-term investments, and said the offering extended its expected cash runway into mid-2027.

Cabaletta Bio, Inc. (NASDAQ:CABA) is a late-stage clinical biotechnology company developing engineered T-cell therapies for autoimmune diseases across rheumatology, neurology, and dermatology.

4. Autolus Therapeutics plc (NASDAQ:AUTL)

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the small-cap stocks with potential to rise 1000 percent. Unlike many biotech companies that are still waiting for their first approved product, Autolus already has a treatment on the market. Its drug AUCATZYL, also known as obe-cel, is approved for adults with a hard-to-treat form of blood cancer called relapsed or refractory B-cell acute lymphoblastic leukemia. In its May 14 first-quarter update, Autolus reported $26.2 million in AUCATZYL net product revenue, up from $9.0 million a year earlier, and said the business reached positive gross margin for the first time.

Autolus also kept its 2026 AUCATZYL revenue guidance at $120 million to $135 million, compared with $74 million in 2025. The company is trying to expand obe-cel beyond its first approved use, with studies in pediatric ALL, lupus nephritis, and progressive multiple sclerosis. On May 21, Autolus said an ASCO abstract from the FELIX study showed a 59% overall remission rate and a 42.6-month median duration of response in patients whose cancer had spread outside the bone marrow, a difficult-to-treat subgroup. Autolus ended the first quarter with $229.4 million in cash, cash equivalents, and marketable securities, enough to fund operations into the fourth quarter of 2027.

Autolus Therapeutics plc (NASDAQ:AUTL) is a commercial-stage biopharmaceutical company developing programmed T-cell therapies for cancer and autoimmune diseases.

3. Compass Therapeutics, Inc. (NASDAQ:CMPX)

Compass Therapeutics, Inc. (NASDAQ:CMPX) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story is tovecimig, an experimental cancer treatment being developed for biliary tract cancer, which affects the bile ducts, gallbladder, or nearby digestive organs. In its May 5 first-quarter update, Compass said tovecimig had received FDA Orphan Drug Designation in April, a status meant for treatments targeting rare diseases. The company also said it planned to meet with the FDA ahead of a planned approval application later in 2026.

Compass is trying to move tovecimig toward regulators after a late-stage study showed stronger tumor response and longer disease control than chemotherapy alone. The company also said a Phase 1 study had begun for CTX-10726, another experimental cancer treatment, with initial data expected in the fourth quarter of 2026. Compass ended the first quarter with $195 million in cash and marketable securities, which it expects to fund operations into 2028. That gives the company time to push its lead cancer program through the next regulatory steps while also advancing earlier pipeline assets.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a clinical-stage biotechnology company developing antibody-based treatments for cancer.

2. Altimmune, Inc. (NASDAQ:ALT)

Altimmune, Inc. (NASDAQ:ALT) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead drug candidate, pemvidutide, is being developed for MASH, a serious liver disease tied to fat buildup, inflammation, and scarring in the liver. On May 28, Altimmune said new 48-week data from its IMPACT Phase 2b study showed improvements in several health measures linked to MASH, including triglycerides, cholesterol, body weight, waist size, and blood pressure. At the 1.8 mg dose, patients with elevated baseline levels saw triglycerides fall 23.7% and total cholesterol fall 15.4% versus placebo.

Altimmune is trying to move pemvidutide into a larger Phase 3 study rather than leaving the program at mid-stage data. In its May 13 first-quarter update, the company said it expects to start the PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data expected in 2029. The company is also testing pemvidutide in alcohol use disorder and alcohol-associated liver disease, with data or enrollment updates expected later in 2026. Altimmune had about $535 million in cash, cash equivalents, and short-term investments as of April 30, 2026, giving it a stronger balance sheet as the program moves into larger trials.

Altimmune, Inc. (NASDAQ:ALT) is a late clinical-stage biotechnology company developing pemvidutide for serious liver diseases, including MASH, alcohol use disorder, and alcohol-associated liver disease.

1. Silence Therapeutics plc (NASDAQ:SLN)

Silence Therapeutics plc (NASDAQ:SLN) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead story is divesiran, an experimental treatment for polycythemia vera, a rare blood cancer in which the body makes too many red blood cells. Patients often need repeated blood draws to lower red blood cell levels, and Silence is trying to reduce that treatment burden with a drug designed to turn down a disease-related gene signal.

On June 11, Silence presented follow-up Phase 1 data from the SANRECO study at the European Hematology Association 2026 Congress. In the six months before treatment, 21 patients needed 80 blood draws. During active treatment, that number fell to 5, and only 4 more blood draws were reported during the 16-week follow-up period after the final dose. Among 14 patients with longer follow-up, the median time to the first blood draw was 287 days.

The next test is larger. Silence said its Phase 2 SANRECO study remains on track for top-line results in August 2026. The company ended the first quarter with $70.1 million in cash, cash equivalents, and short-term investments.

Silence Therapeutics plc (NASDAQ:SLN) is a clinical-stage biotechnology company developing RNA-based medicines for blood disorders, cardiovascular disease, and rare diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.